Related Experiment Video
Updated: Dec 13, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
Kimberly S Corbin1, William G Breen1, Jonathan B Strauss2
1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.
Abstract:
Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigilant of unexpected toxicities with newly approved therapies.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
07:08Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
Published on: August 31, 2022